Post-Watchman Device Management in Primary Care

Critical Complications to Monitor

The American College of Cardiology recommends that primary care physicians monitor for device-related thrombus, which occurs in 1.7-7.2% of patients and significantly increases stroke risk, with a hazard ratio of 4.6 for high-grade thrombus 2, 3
High-risk patients requiring closer surveillance include those with non-paroxysmal atrial fibrillation, renal insufficiency, history of TIA or stroke, deep device implantation, hypercoagulable disorders, and left ventricular dysfunction 1, 2
Any new neurological symptoms warrant immediate evaluation, as device-related thrombus-associated stroke risk is substantial 2
The American Heart Association notes that any peridevice leak detected on TEE, regardless of size, increases risk of thromboembolism, major bleeding, and all-cause death 2, 1
Patients with detected leaks require continued anticoagulation and cannot safely discontinue warfarin at 45 days, according to the American College of Cardiology 1

The American College of Cardiology recommends warfarin plus aspirin 81-162 mg daily for the first 45 days after device implantation, with a target INR of 2.0-3.0 1, 4
Close INR monitoring is essential during this high-risk bleeding period, particularly in elderly patients, as stated by the American Geriatrics Society 1
TEE must be performed at 45 days to evaluate for device-related thrombus and peridevice leak before discontinuing warfarin, according to the American Heart Association 1

The American College of Cardiology recommends monitoring for signs of hemorrhage, such as unexplained bruising, hematuria, melena, hematemesis, or intracranial bleeding symptoms 4
The device reduces hemorrhagic stroke risk compared to long-term warfarin, but the initial 6-month antithrombotic period still carries bleeding risk, as noted by the American Heart Association 1, 4

The American College of Cardiology recommends that patients with concurrent coronary artery disease who require dual antiplatelet therapy for stent thrombosis prevention should remain on dual antiplatelet therapy beyond 6 months, not transition to aspirin monotherapy 4
Patients over 85 have significantly higher procedural stroke risk and warrant closer monitoring, according to the American Geriatrics Society 3